Critical Survey: Mylan (MYL) versus NephroGenex (NRXGQ)

Mylan (NASDAQ: MYL) and NephroGenex (OTCMKTS:NRXGQ) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, risk, institutional ownership, profitability, valuation, earnings and analyst recommendations.

Analyst Recommendations

This is a summary of recent ratings for Mylan and NephroGenex, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Mylan 0 7 10 0 2.59
NephroGenex 0 0 1 0 3.00

Mylan currently has a consensus target price of $40.96, indicating a potential upside of 9.40%. NephroGenex has a consensus target price of $17.50, indicating a potential upside of 624,900.00%. Given NephroGenex’s stronger consensus rating and higher possible upside, analysts plainly believe NephroGenex is more favorable than Mylan.

Volatility & Risk

Mylan has a beta of 1.38, indicating that its share price is 38% more volatile than the S&P 500. Comparatively, NephroGenex has a beta of -0.98, indicating that its share price is 198% less volatile than the S&P 500.

Profitability

This table compares Mylan and NephroGenex’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Mylan 7.28% 20.63% 7.19%
NephroGenex N/A -211.97% -105.90%

Institutional and Insider Ownership

73.9% of Mylan shares are held by institutional investors. 0.7% of Mylan shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Earnings & Valuation

This table compares Mylan and NephroGenex’s gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Mylan $11.08 billion 1.81 $480.00 million $1.66 22.55
NephroGenex N/A N/A N/A ($2.32) 0.00

Mylan has higher revenue and earnings than NephroGenex. NephroGenex is trading at a lower price-to-earnings ratio than Mylan, indicating that it is currently the more affordable of the two stocks.

Summary

Mylan beats NephroGenex on 9 of the 11 factors compared between the two stocks.

About Mylan

Mylan N.V. is a global pharmaceutical company. The Company develops, licenses, manufactures, markets and distributes generic and branded generic products for resale by others; specialty pharmaceuticals, and active pharmaceutical ingredients (APIs). It operates through two segments: Generics and Specialty. Its Generics segment primarily develops, manufactures, sells and distributes generic or branded generic pharmaceutical products in tablet, capsule, injectable, transdermal patch, gel, cream or ointment form, as well as API. Its Specialty segment is focused on respiratory and allergy therapies. The EpiPen Auto-Injector, which is used in the treatment of severe allergic reactions, is an epinephrine auto-injector. Its Perforomist Inhalation Solution is a long-acting beta2-adrenergic agonist indicated for the maintenance treatment of bronchoconstriction in chronic obstructive pulmonary disorder (COPD) patients. The Company also markets ULTIVA, which is an analgesic agent.

About NephroGenex

NephroGenex, Inc. is a pharmaceutical company. The Company is focused on the development of therapeutics to treat kidney disease. The Company has paused the clinical program of its product candidate, oral Pyridorin, for the treatment of diabetic nephropathy. The Company was primarily focused on the Phase III Pyridorin program, and other planned clinical and nonclinical studies and other work needed to submit Pyridorin for acute kidney injury (AKI), as well as the treatment of diabetic nephropathy in patients with Type II diabetes for regulatory approval in the United States and Europe. The Company has not generated any revenues.

Receive News & Ratings for Mylan N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mylan N.V. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply